|
Clinical Trials for Various Cancer Trials |
|
|
|
Dogs with Naturally Occouring Cancer
Eligibility Requirements
• Biopsy diagnosis of a measurable lesion of a naturally‐occurring cancer
• Expected survival ≥ 6 weeks
• Normal CBC and serum creatinine ≤2 mg/dl
Study Objective
This pilot study is to determine the antitumor effects and the toxicity of a folate‐targeted therapy. The goal is to selectively deliver the chemotherapy inside the tumor cells while limiting the exposure to normal cells.
Compensation
Vinblastine‐folate conjugate chemotherapeutic drug provided free. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Phase I Evaluation of Gold Nanorods in Dogs with Solid Tumors
Eligibility Requirements
• Histologically confirmed solid tumor (preferably soft tissue sarcoma, however other sarcomas or carcinomas can be enrolled),
• Age > 1 year
• A tumor amenable to repeat biopsy and must be located on the external part of the body
• A life expectancy of at least 6 weeks
• Not received chemotherapy (including prednisone) or radiation within 3 weeks of study entry and must have recovered from any side effects
• At least 3 weeks apart from any major surgical procedure
• No evidence of metastatic disease
• At least 2 weeks apart from other investigational drug
Study Objective
Nine dogs with solid tumors amenable to repeat biopsy that have failed conventional therapy or for which there is no therapeutic alternative or for which conventional therapy is not desired by the owner will be entered into the study. Following appropriate staging tests (CBC, chemistry panel, and thoracic radiographs) to determine patient eligibility, a baseline biopsy will then be obtained, a portion of which will be placed in formalin for histopathologic analysis, and a second portion of which will be flash frozen for biochemical evaluation. Dogs will be administered gold nanorods at a dose of 25 mg/kg. This dose is based on clinical evaluation of gold nanorods in normal beagle dogs in which doses up to 32 mg/kg were given with no evidence of any adverse events. Approximately 72 hours post nanorod injection, dogs will undergo NIR diode laser treatment until the tumor has been heated to approximately 40C for 1-2 minutes; the entire process is expected to take approximately 5 minutes. Sedation will be administered to allow laser application without patient movement. Dogs will be evaluated 7 days following treatment and on day 14 after treatment, the dog will undergo surgical excision of any remaining tumor. If this is not possible, a second tumor biopsy will be performed to assess the extent of tumor death.
Compensation
The study will cover all costs associated with visits, biopsy, bloodwork and procedures After the study is completed, the client will receive $1000 to be used toward surgery for removal of the remaining tumor, or other treatments if the tumor is not amenable to surgical resection. Owner is responsible for the initial office visit plus $25/visit and any additional costs that arise from prescribed medications, and the treatment of potential complications during the study. Please click on the link for more details.
Location of Trial
Columbus, OH
More information
Evaluation of STA-1474 dosed two consecutive days in dogs with spontaneous solid tumors
Eligibility Requirements
To qualify for enrollment in this study, dogs must have:
• Histologically or cytologically confirmed diagnosis of cancer;
• Age > 1 year;
• No evidence of other illness such as kidney, liver or heart disease;
• At least 2 weeks apart from other investigational drug;
• Must have an estimated life expectancy of at least 8 weeks;
• Prior radiation therapy or chemotherapy must have been completed at least 3 weeks prior to study entry.
Study Objective
The goal of this study is to determine if dosing STA-1474 on two consecutive days can be tolerated, and if so, identify the maximum tolerated dose; and determine the pharmacokinetic profiles of STA-1474 over the course of drug infusion.
Compensation
All costs associated with this study are covered by the study including management of any side effects that may occur. Additionally, clients will receive a $750 credit at the OSU VMC for continued treatment of their dogs cancer. This can be applied to surgery to remove the tumor, or medical therapy/radiation therapy for the tumor. Please click on the link for more details.
Location of Trial
Madison, Wisconsin
More information
Metronomic cyclophosphamide combined with carboplatin for dogs with cancer.
Eligibility Requirements
• Dogs with any type of cancer that are starting treatment with carboplatin chemotherapy are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible (bloodwork, x-rays, +/- ultrasound). They must have good function of the liver and kidneys and acceptable blood cell counts. No concurrent cancer therapy can be given during the study, and a 3-week washout from prior chemotherapy and 6-week washout from prior radiation therapy is required. Non-steroidal anti-inflammatory drugs (NSAIDs) are allowable while on study provided the dog has been receiving the drug from >14 days.
Study Objective
Chemotherapy typically is administered at maximally tolerated (high) doses at regular intervals. Although the chemotherapy drug kills rapidly growing cancer cells, some normal cells (such as those in the bone marrow and intestines) are also affected and a recovery period is needed for these tissues to renew themselves. Unfortunately, this gap in treatment can allow the cancer cells time to grow as well. Research in mice and people has also shown that high-dose chemotherapy may also stimulate production of cells such as circulating endothelial cells (CECs) that likely help tumors develop a new blood supply (angiogenesis) and lead to further growth of the tumor. Metronomic, or daily low dose, chemotherapy has been shown to decrease angiogenesis, thereby decreasing the growth and spread of the cancer cells. The chemotherapy drug cyclophosphamide is frequently used in metronomic chemotherapy protocols; this drug is administered orally at home and is associated with minimal side effects. The goal of this study is to determine whether metronomic cyclophosphamide can safely be combined with maximally tolerated doses of carboplatin and if this combination will decrease the levels of circulating endothelial cells in dogs with cancer.
Compensation
The owner is responsible for scheduling appointments with the oncology clinical trials coordinator and keeping those appointments as required by study protocol. The owner is responsible for the costs of diagnosis and staging of the tumor prior to entering the study. Clients participating in this study will be given special financial considerations. Specifically, the cyclophosphamide therapy will be provided free of charge for the duration of the study. The study will also pay for cost of the first dose of carboplatin (drug only, ~$150), the first three recheck exams, and all blood work and urinalyses. Owners are responsible for all associated costs of carboplatin chemotherapy after the first dose (~$300-350/dose) and any other tests or treatments recommended by the oncology clinician. Please click on the link for more details.
Location of Trial
Fort Collins, CO
More information
Hydroxychloroquine to enhance doxorubicin effectiveness
Eligibility Requirements
I• Dogs with any type of measurable cancer are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible (bloodwork, x-rays, +/- ultrasound, +/- tumor biopsy). They must have good function of the liver and kidneys and acceptable blood cell counts. No concurrent cancer therapy can be given during the study, and a 3-week washout from prior chemotherapy and 6-week washout from prior radiation therapy is required. Owners must consent to a post-mortem examination (autopsy) at the time their pet dies or is euthanized.
Study Objective
This clinical trial is designed to evaluate a form of treatment for dogs with cancer using a combination of the antimalarial drug hydroxychloroquine (HCQ) and the chemotherapy agent doxorubicin (DOX). Recent studies suggest that HCQ can sensitize human tumor cells to the anti-cancer effect of DOX. Recent studies in dogs with skin disease have demonstrated that long-term HCQ treatment appears to be well-tolerated. The combination of these two treatments has not been explored in canine cancer patients. The goal of this study is to determine the maximum tolerated dose of HCQ that can be administered to tumor-bearing dogs when followed by a standard dose of DOX.
Compensation
The owner is responsible for scheduling appointments with the oncology clinical trials coordinator and keeping those appointments as required by study protocol. The owner is responsible for the costs of diagnosis and staging of the tumor prior to entering the study Clients participating in this study will be given special financial considerations. Specifically, the study will pay for many of the costs associated with the study, including recheck examinations, tumor biopsies for the study, and study-related blood tests. The HCQ and DOX are also provided at no cost. The costs of DOX administration and recheck imaging tests such as x-rays or ultrasound, if necessary to determine treatment effectiveness, are the responsibility of the owners. Please click on the link for more details.
Location of Trial
Fort Collins, CO
More information
Funded Clinical Trial for Dogs with Solid Tumors
Eligibility Requirements
Inclusion Criteria Includes:
• Client-owned dogs with solid tumors with a preference for squamous cell carcinoma and sarcomas
• Histologic or cytologic confirmation of tumor diagnosis
• Dogs that have failed standard therapy or whose owners have declined such therapy
• At least one palpable lesion measuring ≥ 1 cm in diameter
• Dogs able to function normally (Modified ECOG Performance Score of 0 or 1)
Exclusion Criteria Includes:
• Evidence of an active bacterial infection based on physical examination and/or complete blood count evaluation
• Received antibiotic therapy within 7 days prior to infusion for a confirmed or suspected infection
• Cancer therapy of any type (chemotherapy, radiation therapy, immunotherapy, etc.) within 3 weeks of study treatment
• Tumors located in areas where abscess development would be catastrophic, such as nasal tumors that extend into the brain or significant pulmonary metastatic disease
Study Objective
A minimum of 100 dogs with solid tumors will be treated with modified anaerobic bacteria. Treated dogs will be monitored closely after treatment with follow-up required at 2,4,7, and 14 days. While the patient remains on study, there will also be rechecks at 1 and 2 months from the initial treatment.
Compensation
Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are attributed to the study drug, the study will pay for medical management of the side effects.
Location of Trial
Various, click for details.
Tinton Falls, NJ
Dogs with any Tumor
Eligibility Requirements
• We are looking for ANY dog breed with ANY tumor type at the moment. We are particularly interested in Golden Retrievers with lymphoma, Scottish terriers with TCC (which will get a little more cash for the cystoscopy) and Cocker Spaniels with oral melanoma.
Study Objective
e have a new tissue collection trial with a great financial incentive for dog owners! We are looking to collect tumor tissue samples, blood and saliva/buccal swab samples to determine turnaround time for sample processing.
Compensation
Financial incentive includes: $140 for the exam, $300 for the biopsy and a further $1000 for other diagnostics and treatment!! Please click on the link for more details.
Location of Trial
Madison, Wisconsin
More information
2 Phase I Clinical Trial of 5-Fluorouracil in Tumor-Bearing Dogs
Eligibility Requirements
1. Dogs with any cytologically and/or histologically confirmed cancer.
2. They may have measurable or microscopic disease to participate.
3. They may have had prior surgery, radiotherapy, and/or chemotherapy. However, there must be at least a four week lapse between any of these treatments and entry into the trial.
4. Dogs may not receive non-steroidal anti-inflammatory drugs (NSAIDs) or steroids while in the study and must undergo a 72 hour washout period if on NSAIDs prior to study initiation.
5. They must have normal organ and bone marrow function and have an expected survival of at least 4 weeks.
6. Owners must sign a consent form.
Study Objective
5-fluoropyrimidime antimetabolite drugs such as 5-fluoruracil (5-FU) are primarily used in human oncology to treat epithelial tumors. Although 5-FU has been used to treat cancer in dogs, its dosage, treatment schedule, and toxicities have never been appropriately investigated. The objectives of this study are to determine the dose-limiting toxicity and maximum tolerated dosage, to establish a safe starting dosage, and to elucidate treatment-related side effects of 5-FU in tumor-bearing dogs
Compensation
The costs of the initial tests, 5-FU treatment, and complete blood counts will be paid by the study if the dog qualifies. Assuming the dog tolerates the first treatment well, treatments may be continued, off study, at the owner’s expense. Complications of chemotherapy will NOT be covered by the study. Please click on the link for more details.
Location of Trial
Georgia
More information
Gemzar (Gemcitabine) for Cats Feline Patients with Any Tumor Type
Eligibility Requirements
• Confirmed diagnosis
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within one weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
Study Objective
The purpose of the study is to determine the dose of Gemcitabine that optimizes tumor control in cats with any type of tumor.
Compensation
This study is Fully Funded. Once enrolled, the study will pay for the office exam, routine bloodwork, administration of the drug and drug. The patient will be required to stay at least part of the day. Please click on the link for more details.
Location of Trial
Davis, California
More information
Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam Canine pets with Anal Sac Andenocarcinoma post surgery
Eligibility Requirements
• none
Study Objective
Comparing the two different agents, Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Compensation
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving. Please click on the link for more details.
Location of Trial
Davis, California
More information
Analysis of Palladia Pharmacokinetics and Pharmacodynamics at Non-Label Dosing
Eligibility Requirements
• Have a sarcoma, carcinoma, melanoma or other solid tumor (excluding histiocytic sarcoma and hemangiosarcoma) that has either failed standard therapy or for which the owner declines standard therapy
• Have a life expectancy of approximately 90 days
• Have completed any chemotherapy or radiation therapy at least 2 weeks prior to enrollment
Study Objective
The goal of this study is to determine the pharmacokinetics (blood levels) of Palladia given to dogs with cancer at doses lower than that recommended on the label.
Compensation
Palladia will be provided at no cost during, and 6 months after the completion of the study representing a savings of $1500-3000 to owners. The owner is responsible for all other costs including office visits and bloodwork. Please click on the link for more details.
Location of Trial
Columbus, Ohio
More information
Phase I Clinical Trial of Vinorelbine in Tumor- Bearing Cats
Eligibility Requirements
• Cats with any cytologically or histologically confirmed cancer are eligible.
• They may have measureable or microscopic disease to participate.
• They may have had prior surgery, radiotherapy. and/or chemotherapy. However, there must be at least a four week lapse between any of these treatments and entry into the trial.
• Cats may not receive non-steroidal anti-inflammatory drugs (NSAIDS) or steroids while in the study and must undergo a 72 hours washout period if on NSAIDS or steroids prior to stduy initiation.
• They must have normal organ and bone marrow function and have an expected survival of at least 4 weeks.
• Owners must sign a consent form.
Study Objective
To determine the dose-limiting toxicity and maximum tolerated dosage, to establish a safe starting dosage, and to elucidate treatment-related side effects of Vinorelbine in tumor-bearing cats.
Compensation
ost of intial tests, chemotherapy and follow-up CBC will be reimbursed if the cat qualifies for the study.Assuming the cat tolerates the dosage well, treatments may be continue every other week, off-study, at the owners expense. Complications of chemotherapy will NOT be covered by the study. Please click on link for more details.
Location of Trial
Athens, GA
More information
IL-12 gene therapy for enhancing therapeutic efficacy of Bleomycin against oral tumors
Eligibility Requirements
• Dogs must have a histopathological diagnosis of oral SCC, oral melanoma or acanthomatous ameloblastona
• Dogs with local or regional but not systemic metastatic disease are eligible for treatment
• Dogs with anticipated survival time without treatment of more than 2 months
• Dogs CANNOT have any history of clinically significant hepatic and/or renal toxicity.
Study Objective
The objective of this study is to evaluate the clinical response of canine oral SCC, oral melanoma or acanthomatous ameloblastoma treated with combination IL-12 and Bleomycin electrochemotherapy vs. Bleomycin electrochemotherapy or IL-12 electrochemotherapy alone.
Compensation
This study is fully funded if you go to LSU. This study is partially funded if you pursue treatment at VOHC. Please click on LSU link for more details.
Location of Trial
Baton Rouge, LA: More information
Norwalk, CT: More information
Development of a canine model of radiotherapy-induced oral mucositis
Eligibility Requirements
• Dogs who have been diagnosed with cancer of the head and neck and evaluated at MJR-VHUP
• Owner has elected to pursue radiation therapy to treat their dog’s cancer
Study Objective
The purpose of this clinical research project is to gather data about the development and progression of oral mucositis and how it affects dogs’ behavior and quality of life. The results will be analyzed in the hope to develop more treatment options and relief for this condition.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Philadelphia, PA
More information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
Offset the cost of biopsy for dogs with lymphoma
Eligibility Requirements
• Dogs with lymphoma, osteosarcoma, oral melanoma, sarcoma, mast cell tumor, primary lung tumor, or hemangiosarcoma
Study Objective
To get a well-described repository of canine tumor tissues as an essential resource to progress new cancer therapies. This resource has been named the Pfizer Inc. CCOGC (Canine Comparative Oncology and Genomics Consortium) Biospecimen Repository.
Compensation
The cost of surgical biopsy collection, a necessary diagnostic step in the majority of patient work-ups, is completely covered in most cases (unless involving open cavity collection).
Location of Trial
Madison, WI
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Canine patients with osteosarcoma, lymphoma, or oral malignant melanoma, mast cell tumors, soft tissue sarcomas/histiocytic sarcoma/malignant histiocytosis, primary pulmonary cancer, hemangiosarcomas
Eligibility Requirements
• Requirements vary for each type of cancer listed above. Please click on link for more details.
Study Objective
The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Davis, CA: More information
North Grafton, MA: More information
Madison, WI: More information
Liposomal clodronate for the treatment of malignant histiocytosis (hystiocytic sarcoma)
Eligibility Requirements
• Dogs must have d iagnosis of malignant hystiocytosis (MH, hystiocytic sarcoma)
• Dogs must have a life expectancy of at least 6 weeks.
• Dogs must have NOT received chemotherapy within 3weeks of starting study.
• Dogs must discontinue any NSAIDS or corticosteroids at least 72 hours prior to starting study.
Study Objective
To determine if clodronate displays any anti-tumor activity against malignant hystiocytosis.
Compensation
This study covers the cost of liposomal clodronate; the owner is responsible for all other costs including office visits and bloodwork.
Location of Trial
Columbus, OH
More information
Cerenia for nausea during administration of DTIC in dogs
Eligibility Requirements
• Any dog receiving DTIC as part of their cancer therapy
Study Objective
The goal of this study is to evaluate the efficacy of an established anti-nausea medication, Cerenia, in controlling emesis developing from DTIC administration.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
North Grafton, MA
More information
Collection of specimens and health information for research
Eligibility Requirements
• Any dog that will be undergoing a surgical procedure as part of his/her treatment.
Study Objective
The collections in these repositories will be used for future investigations by researchers at locations across the country to allow better understanding of canine and human cancers.
Compensation
This study is not funded. Please click on link for more details.
Location of Trial
North Grafton, MA
More information
The role of genetics in cancer that occurs in purebred dogs
Eligibility Requirements
• Cats and dogs with various types of cancers. Please click on link for more details..
Study Objective
There is an association between purebred dogs and the types of cancers that they develop. We believe these associations are due to hereditary factors that have been passed from generation to generation by the selective breeding of purebred dogs. It is our goal to investigate these associations and uncover the link between dog breeds and the kinds of cancers they are at increased risk of developing. This knowledge will aid in understanding the biological processes of cancer and improve our ability to diagnose and treat cancer in dogs.
Compensation
These studies may be partially funded. Please click on link for more details.
Location of Trial
East Lansing, MI
More information
Stomach cancer study in dogs
Eligibility Requirements
• Dogs of the following breeds Chow, Akita, Belgian sheepdog and tervuren, Bouvier, Irish Setter, Keeshond, Norwegian Elkhound and the Scottish Terrier.
o Either showing signs of stomach cancer or have been
diagnosed with stomach cancer OR
o No signs of stomach cancer and at least 8 years old
Study Objective
To determine the cause of stomach cancer in breeds that have an increased risk.
Compensation
This study is not funded. Please click on link for more details.
Location of Trial
East Lansing, MI
More information
Transitional cell carcinoma study in dogs
Eligibility Requirements
• Dogs of the following breeds: Highland White Terrier, Scottish Terrier, Shetland Sheep Dog or Beagle that is over the age of 7
o Either affected (has bladder cancer) OR
o Unaffected (does not have bladder cancer)
Study Objective
To determine the cause of bladder cancer West Highland White Terriers, Scottish Terriers, Shetland Sheep dogs and Beagles.
Compensation
This study is not funded. Please click on link for more details.
Location of Trial
East Lansing, MI
More information
|
| |
|
